Search clinical trials for: JNJ-64041575 (oral suspension formulation)

Total 355 results

Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Healthy

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Janssen Research & Development, LLC

Terminated

Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Janssen Research & Development, LLC

Terminated

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

Australia, France, United Kingdom, Belgium, Taiwan, United States, Spain, Argentina, Mexico, Bulgaria, Malaysia, Japan, Sweden, Korea, Republic of, Canada, Netherlands, Brazil, Germany, Poland
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

United States, Belgium, Canada, Hungary, Japan, Poland
Janssen Research & Development, LLC

Withdrawn

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus (STEP)

Metapneumovirus

Netherlands, United States, France, Taiwan, Korea, Republic of, Australia, Japan, Spain, Malaysia, Russian Federation, Sweden, Poland, Bulgaria, Argentina, Brazil, Ukraine
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

Healthy

United States
Janssen R&D Ireland

Completed

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Healthy Participants

Belgium
Janssen-Cilag International NV

Completed

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

Healthy

Germany
AstraZeneca
Quotient Sciences

Completed

AZD4635 Relative Bioavailability Study (Rel Bio)

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1205

Healthy

Belgium
reMYND

Recruiting

A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

Alzheimer Disease

Netherlands, Spain
Jnana Therapeutics

Recruiting

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Phenylketonuria

United States, Australia
Janssen Sciences Ireland UC

Completed

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Healthy

United Kingdom
Glock Health, Science and Research GmbH

Completed

G-PUR® for Reduced Lead Bioavailability

Lead Exposure

Austria
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Adenocarcinoma of Lung

Spain, Belgium, United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
Vanda Pharmaceuticals

Completed

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Cylene Pharmaceuticals

Unknown

Dose-escalation Study of Oral CX-4945

Breast Cancer | Multiple Myeloma | Advanced Solid Tumors | Inflammatory Breast Cancer | Castleman's Disease

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
Vifor Fresenius Medical Care Renal Pharma
Tigermed Consulting Co., Ltd

Recruiting

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (Patiromer JADE)

Renal Insufficiency, Chronic | Hyperkalemia

China
Vanda Pharmaceuticals

Recruiting

Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances

Sleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological Disorder

United States
Galapagos NV

Terminated

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Healthy

Netherlands
Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Healthy

Belgium
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Healthy

Canada
ReveraGen BioPharma, Inc.

Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Relypsa, Inc.

Terminated

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Hyperkalemia

United States
Relypsa, Inc.

Completed

Patiromer With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Hyperkalemia

United States
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
R-Pharm

Terminated

Phase 1 Trial of Oral Ixabepilone

Advanced Solid Tumors

United States
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Glo Science, Inc.
EEC Institute, Inc.

Completed

Evaluating the Efficacy of a Gum Health Formulation on Teeth Whitening in Patients With Gingivitis and Periodontitis

Periodontal Diseases | Tooth Discoloration

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813

Healthy

Belgium
Relypsa, Inc.

Completed

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) (OPAL)

Chronic Kidney Disease (CKD) | Hyperkalemia (HK)

United States, Croatia, Czechia, Denmark, Georgia, Hungary, Italy, Serbia, Slovenia, Ukraine
Noxopharm Limited

Withdrawn

A Study of Safety and Tolerability of NOX66 in Healthy Volunteers

Healthy Volunteers

Australia
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Healthy

Belgium
ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States

3

Subscribe